Abstract 4138107: Ventricular Tachycardia Mortality Trends in Oncology: Where Are We Now?

Background: Advancements in chemotherapeutic modalities lead to improved cancer survival rates. While the cardiotoxicity related to the therapies is increasingly recognized, real-world data on ventricular tachycardia (VT) mortality among them is limited. Objective: This study sought to determine the longitudinal cardiovascular mortality trends related to ventricular tachycardia in the cancer population. Methods: We queried the CDC WONDER database among patients ≥ 25 years old from 1999 to 2020. Cardiovascular disease was listed as the main cause of death, while VT and cancer were listed as contributing causes of death. We calculated age-adjusted mortality rates (AAMR) per 1,000,000 individuals. We determined the trends over time by estimating the annual percent change (APC) using the Joinpoint regression program. Results: In the study period, there were 3,483 cardiovascular mortalities related to ventricular tachycardia in patients with comorbid cancer. The overall AAMR decreased significantly from 1.28 (95% CI, 1.11-1.44) in 1999 to 0.67 (95% CI, 0.57- 0.77) in 2020, with an average APC of -2.91 (95% CI, -3.95, -1.86). Overall, males had higher AAMR than females (1.25 [95% CI, 1.20 – 1.30] vs. (0.36 [95% CI, 0.34 – 0.39]). African Americans and White patients have comparable AAMR of 0.78 (95% CI, 0.69-0.86) and 0.77 (95% CI, 0.74-0.80), respectively, which were higher than Asians (0.34 [95% CI, 0.25-0.44]) and Hispanics (0.33 [95% CI, 0.27-0.40]). The AAMR was higher in the rural region than in the urban region (0.72 [95% CI, 0.69 – 0.75] vs. 0.76 [95% CI, 0.70 – 0.81]). The West region had the highest AAMR (0.79 [95% CI, 0.74 – 0.85]). Conclusion: Cardiovascular mortality related to VT in patients with comorbid cancer dropped significantly throughout the years. Further targeted approaches are needed to address the disparities in sex, race, and region.